Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study
Emily L. Graul(Emory University), Jennifer K Quint(Roland Hill (United Kingdom)), Clémentine Nordon(AstraZeneca (United Kingdom)), Constantinos Kallis(Imperial College London), Nicholas S. Peters(Imperial College London), Jonathan C. Marshall(AstraZeneca (United Kingdom)), Hannah Whittaker(Imperial College London), Shruti Menon(Memorial Sloan Kettering Cancer Center), Anne E Ioannides(Imperial College London), Kirsty Rhodes(AstraZeneca (United Kingdom))
American Journal of Respiratory and Critical Care Medicine
December 21, 2023
Cited by 79
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
|EBioMedicine|2022|121
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization
|Nature Medicine|2023|96
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America
|The Journal of Allergy and Clinical Immunology In Practice|2022|79